Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis |
| |
Authors: | F. Combarnous D. Fouque N. Bernard R. Boulieu P. Chossegros M. Laville P. Zech |
| |
Affiliation: | (1) Department of Nephrology, Hôpital Edouard Herriot, Lyon, France;(2) Clinical and Nephrological Pharmacology Unit, CNRS, URA 606, Faculty of Pharmacy, Lyon, France;(3) Clinical Pharmacology Unit, Hôpital Cardiologique, Lyon, France;(4) Department of Hepato-gastroenterology, Hôpital de l'Hôtel-Dieu, Lyon, France;(5) Department of Nephrology, Hôpital Edouard Herriot, F-69437 Lyon Cedex 03, France |
| |
Abstract: | The pharmacokinetics of ganciclovir was evaluated in a 73-year old anuric, haemodialyzed patient given 1.25 mg·kg-1 at the end of each haemodialysis session, three times per week.A biexponential decrease in plasma ganciclovir was observed, with a peak concentration of 3.7 mg·1-1 followed by a steady state value of 2.6 mg·1-1 for almost 40 h. The total plasma clearance was 0.05 ml·min-1·kg-1, the volume of distribution at steady state was 0.61·kg-1, the elimination half life was 132 h, the area under curve was 372 g·h·ml-1, the mean residence time was 190 h, and the percentage of ganciclovir cleared from plasma after a 5 h haemodialysis session was 52.1%.The simulated pharmacokinetics over one month, following the same scheme of administration, did not suggest marked accumulation of ganciclovir. These results were obtained after a reduction of 58% in the recommended dose in patients with impaired renal function. |
| |
Keywords: | Ganciclovir Renal failure pharmacokinetics haemodialysis |
本文献已被 SpringerLink 等数据库收录! |
|